Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Scart
Listen to the Q&A, he alluded to issues with reading results on some 3rd party tech. It is for that they’ve written this new software tool. To bridge the gap.
Except for me DB borderline lied as there was never any indication this was needed and secondly the USP was it worked on any tech. Now it works on any tech with the software tool.
@PP I don’t understand what you mean by teething issues..?
“ - CE marking of software - as Marve(?) identified, not on PI radars this was required, plus software release emphasises DB’s highlighted teething issues appear a greater obstacle than PI’s viewed to securing orders.”
Sam I think it would be wrong to say they wouldn’t have normally issued the trading statement when last year they issued on the 9th July and this year on the 10th July sompretty consistent there I reckon.
I think mgt are to blame here. They told us they would update us on sales by end June...They told us today (later than June) that they had 1 million worth of intent...completely different...there are NO SALES that would be recognised as sales. So the world is underwhelmed and the share price falls. I personally am surprised it has only fallen about 20%. I am not a de-ramper. I have a weighted average of 131p so luckier than a lot of people on here....but Mgt here needs to get a grip. No-one should forgive a 2nd failure to deliver...I havent sold yet but the antennae are out for any sniff of failure to deliver
Ps - never thought I’d long for the days of saying “PEEL sitting on the ASK again all day at £1.40...tut, tut”...
Pps - will update objective SWOT tomorrow
PP
Tide of market sentiment towards GDR & Covid clearly out with many PI’s left basking in their birthday suits (me included).
How long you are comfortable / able to sustain the cold &/or humbling and belief tide will be back in depends on patience, nerve and need to be somewhere else!
Personally, I think tide is unlikely to go much further out and is probable to come a long way back in so the LT bathers can splash around again. New bathers clearly welcome and are in for one hell of a paddle!
Away from la playa - today was unexpected, or was it? Hindsight always an aftertimers favourite tipple, but board has highlighted concerns, and to many today has vindicated those concerns and market reacted accordingly:
- Lack of approvals
- Lack of sales (EU??)
- Orders based on approvals too small
- COVID Stock simply overvalued to start with
Whilst other unknown or under appreciated issues had a light shone on:
- CE approval based on 1 open platform suppliers kit but need now to expand to 2 others, I have no idea how materially this has hampered orders but clearly GDR now seeking further approvals for a reason. Should all have been included in initial submission? Maybe not that simple..
- CE marking of software - as Marve(?) identified, not on PI radars this was required, plus software release emphasises DB’s highlighted teething issues appear a greater obstacle than PI’s viewed to securing orders.
- Approvals eg India only submitted mid June, maybe good reason, but to the uninitiated (inpatient investor) this doesn’t stack up.
To others today represents a chance for MM’s to take advantage and cash in on sentiment to lower price and stack up with cheap shares on a UK Covid play which in many opinions is the closest - aside from Novacyt - to securing lucrative approvals, sales and huge margins and commercialising on a cash cow which will be around for foreseeable future:
- Approvals not guaranteed but we’re close to end game (weeks?) on multiple fronts
- Distribution further expanded
- Product for large markets, Africa, India & US, looks extremely strong and well positioned
- ongoing dialogue with NHS progressing (I’m less convinced this will materialise but hey I thought 89p was the bottom today and topped up!)
- Software, only highlighted negative feedback, placated, presuming its good and hospitals willing to utilise
- Software provides bridge for POC product end of year on handheld devices (maybe overreaching here..)
- expanded CE PCR for reason, expect consumer led - eg sales once approved
- £1m preorders even without approvals, expect this will rise considerably when shackles are off.
- Sticky revenue for long period potentially easily offsetting £8m raise & provide rev to leverage buildout of previous core offerings
- US DoD still on play
- Bottom hit (?), placing level should provide nice level to bounce off and put placing issue to bed.
Today highlighted volatility, 20%+/- possible, today caught offside.